Rockefeller Capital Management
IKT icon

Rockefeller Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Rockefeller Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-250
Closed -$2K – 3871
2021
Q3 		$2K Hold
250
– – ﹤0.01% 3442
2021
Q2 		$4K Buy
+250
New +$7.36K ﹤0.01% 3089

Other funds holding IKT

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Rockefeller Capital Management's IKT Position: Q4 2021 in Review

Rockefeller Capital Management sold out of Inhibikase Therapeutics (IKT) in Q4 2021, closing a stake of 250 shares — an estimated $2K sold.

Rockefeller Capital Management first reported a position in IKT in Q2 2021 and held it in 2 quarters. The position peaked at $4K in Q2 2021. 25 funds tracked by Wall St. Rank hold IKT as of Q4 2021.

  • Rockefeller Capital Management reported no remaining Inhibikase Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Rockefeller Capital Management sold 250 Inhibikase Therapeutics shares in Q4 2021, an estimated $2K.
  • Rockefeller Capital Management first reported a position in Inhibikase Therapeutics in Q2 2021 and held it in 2 quarters.
  • Rockefeller Capital Management's Inhibikase Therapeutics position peaked at $4K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q4 2021.

Based on Rockefeller Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.